Vialox
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
A synthetic pentapeptide marketed as a topical alternative to botulinum toxin, blocking acetylcholine at the neuromuscular junction to soften expression lines. The evidence is speculative, resting on in vitro receptor binding rather than independent human trials. Whether it penetrates skin well enough to reach that junction is unresolved. Not an approved drug, sold as a cosmetic ingredient, supply is unregulated research-grade material of uncertain purity.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Vialox (Pentapeptide-3) is a synthetic 5-amino-acid cosmetic peptide developed by Swiss company Pentapharm to reduce wrinkles by relaxing facial muscles. Inspired by a component of temple viper venom (but containing no actual venom), it works similarly in concept to Botox — blocking the nerve signal that tells muscles to contract — but is applied topically in creams and serums rather than injected. It is one of several 'neurotransmitter inhibitor' peptides in the anti-aging skincare market.
How it works in the body
A pentapeptide that acts as a competitive antagonist at the nicotinic acetylcholine receptor at neuromuscular junctions. By competing with acetylcholine, it reduces the signal that tells facial muscles to contract, smoothing expression wrinkles. Works similarly to Syn-Ake but through direct receptor competition.
Research overview
Vialox works by competing with acetylcholine (the neurotransmitter that triggers muscle contraction) at receptors on facial muscle cells, temporarily preventing them from contracting and thus softening expression-related wrinkles. The manufacturer's data shows a 71% reduction in muscle cell contraction in lab tests, and a 28-day human study reported a 49% decrease in wrinkle size and 47% decrease in skin roughness. However, these are the only efficacy data available — no independent peer-reviewed clinical studies have ever been published for Vialox. A 2020 review in Frontiers in Chemistry explicitly noted this gap. A fundamental open question is whether the peptide can penetrate through the skin barrier in sufficient amounts to actually reach facial muscles, as it is water-loving and relatively large for topical absorption.
Who researches Vialox?
Commonly researched by
People researching skin health and rejuvenation
Studied for collagen synthesis, skin repair, or anti-aging skin effects.
People researching reduction of expression wrinkle depth and size
One of the primary studied benefits of Vialox.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(6)
Rated by level of concern
Lack of independent clinical validation
HighPMID 42116636; absence of ClinicalTrials.gov registrations for Vialox/Pentapeptide-3
Uncertain skin penetration and bioavailability
HighNo published permeation data; general topical-peptide delivery constraints
Contact dermatitis or skin irritation
LowPMID 42116636 (HaCaT non-cytotoxic to 1 mg/mL)
Allergic reaction
LowGeneral topical-peptide risk; no peptide-specific case report identified
Quality varies among unregulated products sold online
ModerateFDA cosmetics regulatory framework (no premarket approval for cosmetic ingredients)
Thermal and pH degradation
ModerateGeneral peptide stability chemistry; no Vialox-specific stability study identified
Interaction summary(8)
Rated by direction with this peptide
Botulinum toxin type A (onabotulinumtoxinA and related neuromodulators)
SynergisticTheoreticalBoth act to reduce mimetic muscle contraction, so topical use alongside or between neuromodulator injections is often positioned as complementary, but no trial has tested Vialox with a neuromodulator and any additive effect remains mechanistic speculation given unproven skin penetration.
Mechanism-based; no Vialox-specific data. Adjacent evidence exists only for other topical peptide serums used with BoNT-A (PMID 39496132: Lupin et al., J Drugs Dermatol 2024, acetyl hexapeptide-8 neuro-peptide serum + BTX-A), not for Vialox.
Topical retinoids (tretinoin, adapalene, retinol)
CautionLowRetinoids thin and disrupt the stratum corneum, which may both increase peptide penetration and raise the chance of combined irritation, dryness, and stinging when layered in the same routine.
Established retinoid barrier-disruption pharmacology; no Vialox-specific interaction study
Low-pH exfoliating acids (glycolic, lactic, salicylic acid) and L-ascorbic acid
CautionLowAcidic vehicles can accelerate peptide hydrolysis and reduce the delivered dose, and the combination increases cumulative irritation - a formulation-stability concern rather than a systemic drug interaction.
General peptide stability chemistry; no published Vialox stability data
Non-depolarizing neuromuscular blocking agents (e.g., rocuronium, vecuronium) in patients undergoing anesthesia
CautionTheoreticalVialox is described as a competitive nAChR antagonist at the same receptor class targeted by non-depolarizing blockers, so additive blockade is conceivable in principle, but topical cosmetic exposure produces no measurable systemic peptide levels and no such interaction has ever been reported. (Depolarizing agents such as succinylcholine are excluded here: a competitive antagonist would antagonize rather than potentiate depolarizing blockade, so the original inclusion of succinylcholine was mechanistically incorrect.)
Mechanism-based inference only; no case reports or pharmacokinetic data
Myasthenia gravis and other neuromuscular junction disorders (including patients on pyridostigmine or other cholinesterase inhibitors)
CautionTheoreticalPatients with reduced nAChR reserve are the group in whom any genuine receptor antagonism would matter most, so cosmetic use over large facial areas is reasonably avoided or discussed with a neurologist even though no adverse events have been documented.
Mechanism-based precaution, consistent with labeling caution applied to injectable neuromodulators in NMJ disease; no Vialox-specific reports
Aminoglycoside antibiotics (gentamicin, tobramycin) and other agents that impair neuromuscular transmission
CautionTheoreticalThese drugs independently weaken neuromuscular transmission, so co-exposure is theoretically additive with a nAChR antagonist, though the absence of systemic absorption from a topical cosmetic makes clinically relevant interaction very unlikely.
Known aminoglycoside neuromuscular-blocking pharmacology; no Vialox-specific data
Benzoyl peroxide and other strong topical oxidizers
CautionLowOxidative degradation can inactivate the peptide when applied in the same layer, so separating applications is a formulation-level precaution rather than a safety issue.
General peptide oxidation chemistry; no Vialox-specific stability study
Systemic medications generally (oral and injectable drugs)
NeutralLowWith no evidence of meaningful transdermal systemic absorption, Vialox has no known or plausible pharmacokinetic interactions with oral or injectable medications.
No absorption or pharmacokinetic data indicating systemic exposure
Known risks(6)
Lack of independent clinical validation
ModerateAll efficacy claims derive from manufacturer-sponsored data that has not been independently replicated or published in peer-reviewed journals. Consumers may be paying a premium for unproven benefits. Multiple academic reviews have explicitly flagged this evidence gap.
Uncertain skin penetration and bioavailability
ModerateWhether Vialox penetrates the stratum corneum in sufficient quantity to exert meaningful nAChR antagonism at dermal neuromuscular junctions is unproven. Hydrophilic peptides face well-documented transdermal delivery challenges.
Contact dermatitis or skin irritation
LowAs with any topical bioactive ingredient, some individuals may experience redness, itching, or irritation, particularly at higher concentrations or on sensitive skin. No systematic adverse event data has been published for Pentapeptide-3 specifically.
Allergic reaction
LowPeptides can occasionally trigger allergic or sensitization responses. Though Vialox is synthetic and not derived directly from snake venom, individuals with known peptide sensitivities should patch-test before use.
Quality varies among unregulated products sold online
ModeratePurity, sterility, and formulation quality may vary. Using research-grade peptide on skin without proper formulation carries unknown risks.
Thermal and pH degradation
LowPentapeptide-3 degrades above 40 degrees Celsius and undergoes pH-dependent hydrolysis outside the pH 5-7 range. Improper storage or poorly formulated products may contain degraded peptide with reduced activity or unknown degradation products.
Drug interactions(6)
Botulinum toxin (Botox, Dysport, Xeomin) injections
Theoretical additive effect on neuromuscular blockade. Botox inhibits presynaptic acetylcholine release while Vialox blocks the postsynaptic receptor. In practice, the topical dose of Vialox reaching muscle tissue is likely negligible, so meaningful clinical interaction is improbable. No documented cases of interaction.
Topical retinoids (tretinoin, adapalene, retinol)
No pharmacological interaction expected. Retinoids act on nuclear retinoic acid receptors and modulate gene expression, while Vialox acts on nicotinic acetylcholine receptors. Cosmetic formulation sources indicate compatibility. However, retinoids can compromise the skin barrier and theoretically increase Vialox penetration, which could alter its local effect profile.
Chemical exfoliants (AHAs, BHAs, PHAs)
No direct pharmacological interaction. Exfoliants thin the stratum corneum and may modestly enhance peptide penetration. Formulation sources list Vialox as compatible with chemical exfoliants for multi-modal anti-aging use.
Other neurotransmitter-inhibiting cosmetic peptides (Argireline, SNAP-8, Leuphasyl, SYN-AKE)
Theoretical additive muscle-relaxing effect, as these peptides target different points in the neuromuscular signaling cascade. Some commercial products combine multiple neuromodulating peptides (e.g., Revox Line Relaxer uses five). No adverse interaction data exists for peptide combinations.
Neuromuscular blocking agents (succinylcholine, rocuronium)
Theoretical concern only. Systemic neuromuscular blockers and topical Vialox both affect neuromuscular transmission, but the topical dose reaching systemic circulation is expected to be essentially zero. No clinical relevance for standard topical use.
Cholinesterase inhibitors (donepezil, rivastigmine, pyridostigmine)
Theoretical opposing effects — cholinesterase inhibitors increase acetylcholine levels at the synapse, while Vialox blocks the acetylcholine receptor. Could theoretically reduce local efficacy of either agent. No clinical data; interaction is unlikely given topical application and minimal systemic absorption.
Research & benefits
Evidence base
- Evidence Level
- Preclinical
- Total Studies
- 3
- Human Studies
- 1
All clinical evidence for Vialox comes from proprietary data generated by its manufacturer, Pentapharm Ltd. This includes one in vivo study on women aged 30-60 using a half-face design over 28 days, and in vitro muscle contraction assays. These results have not been independently replicated, published in a peer-reviewed dermatology journal, or subjected to rigorous external review. Multiple peer-reviewed cosmeceutical review articles (Errante et al. 2020; Pai et al. 2017; Yotova et al. 2025) acknowledge the mechanism but explicitly note the absence of independent clinical validation. The parent peptide Waglerin-1 has robust peer-reviewed pharmacological data, but whether the truncated Pentapeptide-3 retains meaningful activity after topical application through the stratum corneum remains unproven by independent research.
Researched for(5)
Rated by confidence in the evidence
Reduction of expression wrinkle depth and size
SpeculativeNo published human trial exists, reduction figures come from unpublished supplier marketing data.
PMID 42116636 (Akhan et al., 'Integrative In Silico and In Vitro Evaluation of Vialox and Leuphasyl Pentapeptides for Antiaging Applications', Chem Biodivers 2026 - in silico/in vitro only, no clinical data). No RCTs indexed for Vialox/Pentapeptide-3 wrinkle endpoints.
Decreased skin roughness
SpeculativeNo peer-reviewed instrumental study exists, roughness figures come from unpublished supplier technical literature.
No PubMed-indexed clinical study; supplier technical dossier only
Muscle relaxation via nAChR antagonism (in vitro)
SpeculativeMechanism is manufacturer-claimed; the 2025 and 2026 studies tested other targets, without directly testing nAChR binding.
PMID 42116636 (docked Vialox/Leuphasyl against MMP-1/8/13 and SIRT-1 with HaCaT cytotoxicity assays; nAChR not tested). No indexed receptor-binding data for Vialox.
Non-invasive alternative to botulinum toxin for expression lines
SpeculativeMarketing framing, not tested head-to-head, delivery to muscle tissue remains undemonstrated.
No comparative trial identified; delivery to NMJ undemonstrated
Compatibility with multi-modal skincare regimens
SpeculativeBased only on keratinocyte non-toxicity data, not on tested regimen combinations.
PMID 42116636 (no HaCaT cytotoxicity up to 1 mg/mL; in silico ADME/tox)
Benefits(5)
Reduction of expression wrinkle depth and size
Pentapharm manufacturer data — 49% decrease in wrinkle size after 28 days of twice-daily topical application in women aged 30-60 (half-face controlled study). No independent peer-reviewed replication.
Decreased skin roughness
Pentapharm manufacturer data — 47% reduction in skin roughness after 28 days of consistent application in the same half-face study. Results measured by profilometric analysis.
Muscle relaxation via nAChR antagonism (in vitro)
Pentapharm in vitro data — 71% reduction in muscle cell contraction within one minute of Vialox exposure, with 58% reduction persisting after two hours. Akhan et al. 2025 modeled other aging-related targets; the study did not test nAChR binding or confirm this mechanism.
Non-invasive alternative to botulinum toxin for expression lines
Conceptual benefit supported by mechanism-of-action similarity to botulinum toxin (both reduce muscle contraction at the neuromuscular junction, via different mechanisms). No head-to-head comparison studies exist. Pentapharm marketed Vialox as 'a highly effective alternative to Botox injections based on synthetic pentapeptides.' Topical application avoids injection-related risks.
Compatibility with multi-modal skincare regimens
Cosmetic formulation data — Vialox is stable in aqueous formulations and compatible with common cosmetic ingredients including hyaluronic acid, niacinamide, vitamin C, retinoids, and other peptides. Suitable for layered anti-aging protocols.
Key studies(5)
Conformational analysis of a toxic peptide from Trimeresurus wagleri which blocks the nicotinic acetylcholine receptor
Original research (structural biology)In vitro (NMR, CD spectroscopy, computational)Sellin LC, Mattila K, Annila A, Schmidt JJ, McArdle JJ, Hyvonen M, Rantala TT, Kivisto T
Biophysical Journal
1996
Determined the 3D solution structure of Waglerin-1 (the parent toxin Vialox is derived from) using 2D NMR and computational methods. Showed the peptide has extended flexible tails defined by a short rigid disulfide-bonded loop. A synthetic analog replacing the two half-cystines was nontoxic, proving the disulfide bond is critical for bioactivity of the full-length toxin.
Residues in the epsilon subunit of the nicotinic acetylcholine receptor interact to confer selectivity of waglerin-1 for the alpha-epsilon subunit interface site
Original research (receptor pharmacology)In vitro (recombinant nAChR expression)Molles BE, Tsigelny I, Nguyen PD, Gao SX, Sine SM, Taylor P
Biochemistry
2002
Demonstrated that Waglerin-1 selectively blocks the adult (epsilon-containing) muscle nicotinic acetylcholine receptor with approximately 3700-fold higher affinity for the alpha-epsilon interface than the alpha-gamma interface, with additional determinants of selectivity over the alpha-delta interface. IC50 of approximately 50 nM. This selectivity underlies the cosmetic rationale for Pentapeptide-3 as a targeted muscle relaxant.
Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy
Review articleComprehensive literature reviewErrante F, Ledwon P, Latajka R, Rovero P, Papini AM
Frontiers in Chemistry
2020
Classified Vialox (Pentapeptide-3) as a neurotransmitter inhibitor peptide acting as an acetylcholine receptor antagonist derived from snake venom. Explicitly noted: 'There are no further investigations directly describing or enhancing anti-wrinkle properties of Vialox. The only available data are provided by the manufacturer.' This review is the most-cited academic source discussing Vialox's evidence limitations.
Viper Venom Botox: The Molecular Origin and Evolution of the Waglerin Peptides Used in Anti-Wrinkle Skin Cream
Original research (evolutionary biology / toxinology)Comparative genomic and proteomic analysisDebono J, Xie B, Violette A, Fourmy R, Jaeger M, Fry BG
Journal of Molecular Evolution
2016
Revealed the molecular origin of waglerin peptides, showing they evolved de novo within the prepro region of the C-type natriuretic peptide gene in Tropidolaemus venoms. Confirmed waglerins as potent inhibitors of the nicotinic acetylcholine receptor and documented their industrial application in anti-wrinkle skin cream products to paralyze facial muscles and reduce wrinkle formation.
Quantum Chemical, Spectroscopic and In Silico (Molecular Docking, Molecular Dynamic and ADME) Studies on Anti-Aging Pentapeptide-3 (Vialox)
Computational study (in silico)Single compound computational analysisAkhan D, Bicak B, Kecel Gunduz S, Akalin E
International Journal of Quantum Chemistry
2025
First dedicated peer-reviewed computational study of Pentapeptide-3 (Vialox). Used DFT/B3LYP with 6-31++G(d,p) basis set for geometric optimization, followed by molecular docking and dynamics simulations. Predicted interactions with TGF-beta receptor-1, TNF-alpha, MAPK14 and AKT-1; molecular dynamics examined TGF-beta receptor-1 and MAPK14. ADME analysis supported Pentapeptide-3 as a viable cosmeceutical candidate.
Regulation & availability
Why researchers look at it
The manufacturer reports a 49% decrease in wrinkle size and 47% decrease in roughness after 28 days, but no independent peer-reviewed human efficacy trial has been identified, a gap explicitly noted in a 2020 Frontiers in Chemistry review. Academic preclinical studies appeared in 2025 and 2026. Among neurotransmitter-inhibiting cosmetic peptides, Argireline has substantially more independent evidence. Until independent trials validate the claims and resolve whether this hydrophilic peptide can penetrate skin in sufficient quantities, efficacy remains an open question.
- Estimated cost
- $20-60/mo in OTC serums
- FDA status
- NOT applicable as a drug — Vialox is a cosmetic ingredient, not a pharmaceutical. The FDA does not approve or reject cosmetic ingredients before they go to market. Under the Modernization of Cosmetics Regulation Act (MoCRA, enacted December 2022), cosmetic manufacturers must register facilities, list products and ingredients, report adverse events, and substantiate product safety, but pre-market FDA approval is not required. Pentapeptide-3 is listed in the International Nomenclature of Cosmetic Ingredients (INCI) database as a legitimate cosmetic ingredient. However, if a product containing Vialox makes drug-like claims (e.g., 'paralyzes muscles' or 'blocks acetylcholine receptors'), the FDA could classify it as an unapproved drug and take enforcement action. Cosmetic claims must be limited to appearance-related language (e.g., 'reduces the appearance of wrinkles'). The Cosmetic Ingredient Review (CIR) panel has assessed several pentapeptide ingredients (e.g., Palmitoyl Pentapeptide-4) but has not published a specific safety assessment for Pentapeptide-3 (Vialox) as of 2026. Pentapeptide-3 does NOT appear on the FDA's list of bulk drug substances presenting significant safety risks for compounding, as it is not used in compounded medications.
- WADA status
- Vialox is not specifically named in the 2026 WADA Prohibited List. That alone does not establish permission: the list includes broad classes and S0 non-approved pharmacological substances. A compound-specific anti-doping determination was not identified.
- Prescribability
- Not prescribable. Vialox is not a pharmaceutical drug and has no medical indication. It is a cosmetic active ingredient regulated under cosmetic law, not drug law. In the United States, cosmetic ingredients do not require FDA pre-market approval, but products must comply with the Modernization of Cosmetics Regulation Act (MoCRA, December 2022), which mandates facility registration, product listing, adverse event reporting, and safety substantiation. It is not compounded by pharmacies and exists entirely within the cosmetics sector.
- Availability
- Vialox is sold as a raw cosmetic ingredient. It appears as an active ingredient in various anti-aging creams, serums, and eye treatments from cosmetic brands. It is less commonly found in finished products compared to SYN-AKE (Tripeptide-3) or Argireline (Acetyl Hexapeptide-8), which dominate the market for neurotransmitter-inhibiting cosmetic peptides. No prescription is required. This is purely a cosmetic ingredient, not a drug.
International status
EU
Available OTC in cosmetics (INCI listed)
US
Available OTC in cosmetic products (not a drug)
Worldwide
Regulated as cosmetic ingredient, not pharmaceutical
Regulatory timeline(10)
- 1948Pentapharm Ltd. founded in Aesch, Basel, Switzerland by Viktor Sturm and Dr. Edmund Percs. Initially focused on active pharmaceutical ingredients extracted from natural sources, including snake venom components.
- 1992First characterization of Waglerin-1 peptide from Tropidolaemus wagleri venom. Schmidt et al. publish molecular properties and structure-function relationships (PMID 1440639). Aiken et al. describe neuromuscular blocking activity (PMID 1359525).
- 2002Molles et al. publish definitive receptor selectivity study showing Waglerin-1 selectively blocks the epsilon form of muscle nAChR with 2000-fold preference (PMID 12069578). This pharmacological understanding underpins cosmetic peptide development.
- 2003-2005Pentapharm develops and launches Vialox (Pentapeptide-3) as a commercial cosmetic active ingredient, marketed as a topical alternative to Botox for expression lines. Proprietary in vitro and in vivo studies conducted during this period.
- 2006Pentapharm's related product SYN-AKE (Tripeptide-3), another Waglerin-1-inspired peptide, wins the Swiss Technology Award. Both products are marketed as part of Pentapharm's anti-aging cosmetic active ingredient portfolio.
- 2007-07DSM Nutritional Products acquires Pentapharm Ltd. Vialox and SYN-AKE become part of DSM's extended cosmetic active ingredients portfolio.
- 2016Fry et al. publish evolutionary origin study of waglerin peptides used in anti-wrinkle skin cream (J Mol Evol, PMID 27864608), providing academic context for the commercial application of Waglerin-1 derivatives.
- 2020Errante et al. publish comprehensive cosmeceutical peptide review (Frontiers in Chemistry, PMID 33195061), noting Vialox has no independent clinical validation — 'the only available data are provided by the manufacturer.'
- 2022-12US Modernization of Cosmetics Regulation Act (MoCRA) enacted, imposing new requirements on cosmetic manufacturers including facility registration, product listing, and safety substantiation — applicable to products containing Vialox.
- 2025Akhan publishes first dedicated peer-reviewed computational study of Pentapeptide-3 (Vialox) using quantum chemical, molecular docking, dynamics, and ADME methods (Int J Quantum Chem). Yotova et al. publish market analysis showing synthetic snake venom peptides present in 81% of viper-venom-themed cosmetic products.
Sources & FAQs
Research sources(18)
- PubChem — Vialox Peptide (Pentapeptide-3), CID 11605666
- Schmidt et al. 1992 — Molecular properties and structure-function of lethal waglerin peptides
- Aiken et al. 1992 — Novel peptide toxin from Trimeresurus wagleri blocks neuromuscular transmission
- Schmidt et al. 1995 — Effects of waglerin-I on neuromuscular transmission
- McArdle et al. 1996 — Conformational analysis of waglerin-1, nAChR blocker
- Molles et al. 1999 — Residues at alpha and epsilon subunit interfaces mediating waglerin-1 selectivity
- Molles et al. 2002 — Waglerin-1 selectively blocks epsilon form of muscle nAChR
- Gorouhi & Maibach 2009 — Cosmeceutical peptides review (Int J Dermatol)
- Fry et al. 2016 — Viper Venom Botox: molecular origin of waglerin peptides in anti-wrinkle cream
- Errante et al. 2020 — Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy
- Ugur Calis et al. 2021 — Usage of Synthetic Peptides in Cosmetics for Sensitive Skin
- Vassilev et al. 2025 — Peptides: Emerging Candidates for Prevention and Treatment of Skin Senescence
- Yotova et al. 2025 — Viper Venom and Synthetic Peptides: Emerging Active Ingredients in Anti-Ageing Cosmeceuticals
- Katsara et al. 2025 — Current Approaches in Cosmeceuticals: Peptides, Biotics and Marine Biopolymers
- Akhan 2025 — Quantum Chemical, Spectroscopic and In Silico Studies on Pentapeptide-3 (Vialox)
- CIR — Safety Assessment of Pentapeptides as Used in Cosmetics (related compounds)
- Pentapharm Ltd. — Company website (manufacturer of Vialox)
- WADA 2026 Prohibited List
Frequently asked questions(5)
Is Vialox the same as SYN-AKE?
No. Both are synthetic peptides inspired by Waglerin-1 snake venom and both were developed by Pentapharm, but they are different molecules. Vialox is Pentapeptide-3 (Gly-Pro-Arg-Pro-Ala-NH2, 5 amino acids, MW 495.58). SYN-AKE is Tripeptide-3 (beta-Ala-Pro-Dab-NH-benzyl, 3 amino acids with a non-natural backbone). Both act as nicotinic acetylcholine receptor antagonists, but SYN-AKE has greater commercial adoption and won the Swiss Technology Award in 2006. SYN-AKE is found in approximately 81% of snake-venom-themed cosmetic products, while Vialox is less commonly used.
Does Vialox actually work like Botox?
The comparison is mechanistically imprecise. Botox (botulinum toxin) works presynaptically by cleaving SNARE proteins to prevent acetylcholine vesicle release at the neuromuscular junction. Vialox works postsynaptically by blocking the acetylcholine receptor. Both ultimately reduce muscle contraction, but through different molecular targets. More importantly, Botox is injected directly into muscle tissue at precise doses by a medical professional, while Vialox is applied topically to the skin surface and must penetrate the stratum corneum to reach target receptors — a significant barrier for hydrophilic peptides. There are no head-to-head comparison studies, and the topical effect of Vialox is almost certainly orders of magnitude weaker than injected Botox.
Are the clinical results for Vialox trustworthy?
The 49% wrinkle reduction and 47% skin roughness reduction claims come exclusively from manufacturer (Pentapharm) data. This data has not been independently replicated, published in a peer-reviewed dermatology journal, or subjected to rigorous external review. Multiple academic reviews (Errante et al. 2020; Pai et al. 2017) explicitly note this limitation. Manufacturer-sponsored data in the cosmetics industry is common but is generally considered lower-quality evidence than independent clinical trials. The in vitro muscle contraction data (71% reduction in 1 minute) was performed on isolated muscle cells, which is not representative of topical application on intact human skin with its stratum corneum barrier.
Can Vialox penetrate the skin to reach muscle cells?
This is the central unresolved question. Vialox is a hydrophilic pentapeptide (MW ~496 Da) that must cross the lipophilic stratum corneum to reach neuromuscular junctions in the dermis or deeper tissue. Peer-reviewed literature on topical peptide delivery consistently notes that skin penetration is a major challenge for hydrophilic peptides. Advanced delivery systems (nanoemulsions, liposomes, microneedles) can improve penetration, but standard cream/serum formulations likely deliver very limited quantities to target tissues. No published study has measured Vialox skin penetration or dermal bioavailability in humans.
Is Vialox safe for long-term use?
As a topical cosmetic ingredient, Vialox has a favorable theoretical safety profile. It is a small peptide applied externally, not injected, and systemic absorption is expected to be minimal. No serious adverse events have been reported in the cosmetic literature. However, the CIR has not published a dedicated safety assessment for Pentapeptide-3. General risks of topical peptides include contact dermatitis, irritation in sensitive individuals, and potential allergic reactions, though these are rare. Long-term safety data from controlled studies do not exist.